Vascular endothelial growth factor in predicting outcome in breast cancer [2]

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8752-8753

  Krippl, Peter ^a   Langsenlehner, Uwe ^a   Samonigg, Hellmut ^a   Renner, Wilfried ^a   Köppel, Herwig ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; DRUG TARGETING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; METASTASIS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11144226349     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1211     Document Type: Letter

References (3)

1. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-16.
2. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468-71.
3. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443-8.